Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$36.91 USD

36.91
4,316,313

-1.06 (-2.79%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $36.92 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Why Baxter (BAX) Could Beat Earnings Estimates Again

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Trina Mukherjee headshot

3 Medical Products Stocks Poised to Beat This Earnings Season

The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.

Is Baxter International (BAX) Outperforming Other Medical Stocks This Year?

Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3

McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.

Change Healthcare (CHNG) Q3 Earnings in Line, Revenues Beat

Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates

Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.

Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.

AmerisourceBergen (ABC) Q1 Earnings Lag Estimates, Revenues Beat

AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.

PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.

Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.

Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe

Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.

NextGen's (NXGN) Integrated Platform to Enhance Tribal Health

NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.

CVS Health (CVS) Hits a 52-Week High: What's Driving It?

Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.

Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus

Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.

Here's Why You Should Invest in Henry Schein (HSIC) Now

Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.

The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips

Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.

Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy

Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.

John Blank headshot

Oxygen from Earnings: Global Week Ahead

In the Global Week Ahead, Q4 S&P500 earnings will supply the latest details on how major global companies are dealing with rising wage cost pressures.

Medtronic (MDT) Undertakes Investment to Advance STEM Education

The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.

Catalent (CTLT) to Advance Oral Drug Development With New Launch

Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.

Here's Why You Should Retain Chemed (CHE) Stock for Now

Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.

Abiomed (ABMD) Reports Positive Data Backing preCARDIA System

Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.

Is ATI Physical Therapy, Inc. (ATIP) Outperforming Other Medical Stocks This Year?

Here is how ATI Physical Therapy, Inc. (ATIP) and Baxter International (BAX) have performed compared to their sector so far this year.